Cargando…

NOX2: a determinant of acute myeloid leukemia survival

Detalles Bibliográficos
Autor principal:	Jones, Courtney L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614518/ https://www.ncbi.nlm.nih.gov/pubmed/35172567 http://dx.doi.org/10.3324/haematol.2022.280677

Ejemplares similares

A 29‐gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival
por: Ijurko, Carla, et al.
Publicado: (2022)

Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML)
por: Demircan, Muhammed Burak, et al.
Publicado: (2022)

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias
por: Paolillo, Rosa, et al.
Publicado: (2022)

Differentiation and Cell Survival of Myeloid Leukemia Cells
por: Studzinski, George P., et al.
Publicado: (2012)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing?
por: Thol, Felicitas
Publicado: (2022)

Current treatment for pediatric acute myeloid leukemia
por: Im, Ho Joon
Publicado: (2018)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
por: Greiner, Jochen
Publicado: (2019)

Pulling the Pin on NPMc(+) acute myeloid leukemia
por: Kats, Lev M.
Publicado: (2021)

Will immune therapy cure acute myeloid leukemia?
por: Gale, Robert Peter
Publicado: (2019)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

miRNAs as prognostic predictors in acute myeloid leukemia
por: Machado-Neto, João Agostinho, et al.
Publicado: (2023)

Unbiased decision-making for acute myeloid leukemia still needed
por: Eisfeld, Ann-Kathrin
Publicado: (2022)

Lessons learned from therapy-related acute myeloid leukemia
por: Kayser, Sabine
Publicado: (2022)

Disrupting autophagy in FLT3-mutant acute myeloid leukemia
por: Grant, Steven
Publicado: (2022)

The changing face of acute myeloid leukemia therapeutics in the elderly population
por: Daver, Naval, et al.
Publicado: (2015)

Proteomics: a new era in pediatric acute myeloid leukemia research
por: Lamba, Jatinder K., et al.
Publicado: (2022)

A novel approach to overcome drug resistance in acute myeloid leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia
por: Roma, Alessia, et al.
Publicado: (2023)

Deregulation of the CDX2-KLF4 axis in acute myeloid leukemia and colon cancer
por: Rouhi, Arefeh, et al.
Publicado: (2013)

Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?
por: Ganser, Arnold
Publicado: (2022)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia
por: Freeman, Sylvie D.
Publicado: (2022)

CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia
por: Halpern, Anna B., et al.
Publicado: (2018)

ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia
por: Hellmich, Charlotte, et al.
Publicado: (2020)

An exciting RXRA mutant revives interest in retinoids for acute myeloid leukemia
por: Qiu, Fang, et al.
Publicado: (2021)

Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?: Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies
por: Stemler, Jannik, et al.
Publicado: (2022)

Epidemiological evaluation and survival of children with acute myeloid leukemia
por: Morais, Rahuany Velleda de, et al.
Publicado: (2020)

Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest?
por: Atallah, Ehab
Publicado: (2022)

BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia
por: Stone, Richard M.
Publicado: (2020)

Venetoclax response prediction in acute myeloid leukemia: are we Finnish-ed with uncertainty?
por: Stevens, Brett, et al.
Publicado: (2023)

Editorial to the Special Issue “Recent Advances in Biochemical Mechanisms of Acute Myeloid Leukemia”
por: Mesuraca, Maria, et al.
Publicado: (2023)

Immune control in chronic myeloid leukemia
por: Ilander, Mette, et al.
Publicado: (2017)

Targeting PR1 in myeloid leukemia
por: Alatrash, Gheath, et al.
Publicado: (2017)

The transformative journey of chronic myeloid leukemia
por: Neelakantan, Pratap, et al.
Publicado: (2018)

A Critical History of Chromic Myeloid Leukemia
por: Baccarani, Michele, et al.
Publicado: (2014)

Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions
por: Stevens, Alexandra M., et al.
Publicado: (2021)

Kinetics matter: prognostic implications of early bone marrow assessment in acute myeloid leukemia
por: Perner, Florian
Publicado: (2021)

Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia
por: Kim, Seon Young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i5mbcqn8e9r29pdavteejbpq83